- Home
- ALT vs BLND Comparison
ALT vs BLND Comparison
Compare ALT & BLND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALT | BLND |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.5M | 365.1M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ALT | BLND |
|---|---|---|
| Price | $2.96 | $1.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $17.67 | $4.13 |
| AVG Volume (30 Days) | 3.4M | ★ 3.7M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.37 | ★ 58.33 |
| EPS | N/A | ★ N/A |
| Revenue | $41,000.00 | ★ $123,585,000.00 |
| Revenue This Year | N/A | $12.62 |
| Revenue Next Year | N/A | $14.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 105.00 | N/A |
| 52 Week Low | $2.80 | $1.33 |
| 52 Week High | $7.73 | $4.49 |
Technical Indicators
Market Signals| Indicator | ALT | BLND |
|---|---|---|
| Relative Strength Index (RSI) | 36.10 | 37.73 |
| Support Level | $2.87 | $1.39 |
| Resistance Level | $4.25 | $2.00 |
| Average True Range (ATR) | 0.17 | 0.13 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 17.26 | 9.37 |
Price Performance
Historical ComparisonAbout ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About BLND Blend Labs Inc.
Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segment is Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience. The key revenue for the company is generated from the Blend Platform segment. Company has it's assets in united states, India and Mexico regions.